DARE — Daré Bioscience, Inc.

Summary of Dare Bioscience Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• Cash and cash equivalents stood at approximately $18.5 million with working capital of about $0.5 million.
• SG&A expenses for Q1 2026 were approximately $2.2 million, slightly down from $2.3 million in Q1 2025.
• R&D expenses were around $0.7 million, significantly lower than $2.3 million in the prior year, largely due to nondilutive grant funding which offset R&D costs.
• Contra R&D funding was approximately $3.5 million, indicating a higher actual R&D investment than reported.
• The company expects to begin recording product revenue from DARE to PLAY in Q3 2026 and anticipates revenue from Flora Sync LF5 starting in June 2026.

2. Strategic Updates and Business Highlights:

• Dare is focused on a dual-path strategy: commercializing proprietary formulations through 503B compounding while pursuing FDA approval for select products.
• The company is preparing to launch DARE to PLAY, a topical arousal cream, with positive reception from healthcare providers at the ACOG conference.
• Flora Sync LF5, a vaginal probiotic, is set to launch commercially in June 2026, marking the first direct product revenue for Dare.
• The pipeline includes several innovative products targeting women's health issues, including DARE to RECLAIM (bioidentical hormone therapy) and Ovaprene (hormone-free contraceptive), both advancing through clinical trials.

3. Forward Guidance and Outlook:

• The company aims to establish a multiproduct revenue profile by 2026 and 2027, with significant milestones expected in product launches and revenue generation.
• Anticipated revenue from DARE to PLAY and Flora Sync LF5 is expected to support ongoing operations and reduce reliance on equity financing.
• The company plans to engage with the FDA regarding interim findings from the Ovaprene trial, which has shown promising safety data.

4. Bad News, Challenges, or Points of Concern:

• The company noted that it does not have a full 12 months of cash runway without considering projected revenue inflows, indicating a potential need for future capital raises.
• The launch of DARE to PLAY has faced delays primarily due to the complexities of state-specific registrations and ensuring compliance with Good Manufacturing Practices (GMP).
• There are ongoing challenges related to the competitive landscape in women's health, with many new entrants into the market.

5. Notable Q&A Insights:

• In response to questions about the Ovaprene trial, management indicated that while the timing of data readouts could be affected by enrollment and cycle completion, positive safety signals have been observed.
• Regarding the DARE to PLAY launch, management emphasized the importance of ensuring readiness and compliance from their outsourcing partner, Bravado, to meet commercial demand effectively.
• The management acknowledged the need for future capital raises but highlighted the importance of upcoming product revenues as a means to support growth and reduce shareholder dilution.

Overall, Dare Bioscience is positioned for significant growth in the women's health sector, with a strong pipeline and upcoming product launches, although it faces challenges related to cash runway and market competition.